Stockscreener 앱 받기
12.85
6.00%
-0.82
시간 외 거래:
12.85
전일 마감가:
$13.67
열려 있는:
$13.75
하루 거래량:
1.68M
Relative Volume:
0.97
시가총액:
$2.05B
수익:
$113.31M
순이익/손실:
$-57.51M
주가수익비율:
-9.4485
EPS:
-1.36
순현금흐름:
$-20.55M
1주 성능:
-21.84%
1개월 성능:
-16.07%
6개월 성능:
+105.27%
1년 성능:
+133.21%
1일 변동 폭
$12.76
$13.78
1주일 범위
$12.76
$16.71
52주 변동 폭
$3.50
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
명칭
Wave Life Sciences Ltd
전화
617-949-2900
주소
7 STRAITS VIEW, SINGAPORE
WVE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| WVE | 12.85 | 2.05B | 113.31M | -57.51M | -20.55M | -1.36 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-27 | 재개 | JP Morgan | Overweight |
| 2024-09-19 | 개시 | B. Riley Securities | Buy |
| 2024-09-09 | 개시 | JP Morgan | Overweight |
| 2024-05-15 | 개시 | Wells Fargo | Overweight |
| 2023-12-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Raymond James | Outperform |
| 2023-05-24 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-15 | 재개 | H.C. Wainwright | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-31 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-07-15 | 개시 | Cowen | Market Perform |
| 2019-04-17 | 재확인 | H.C. Wainwright | Buy |
| 2018-08-07 | 개시 | Stifel | Buy |
| 2018-07-23 | 개시 | H.C. Wainwright | Buy |
| 2018-03-19 | 재확인 | Mizuho | Buy |
| 2017-02-15 | 개시 | H.C. Wainwright | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | JMP Securities | Mkt Outperform |
| 2015-12-07 | 개시 | Jefferies | Buy |
| 2015-12-07 | 개시 | Leerink Partners | Outperform |
| 2015-12-07 | 개시 | Sun Trust Rbsn Humphrey | Buy |
모두보기
Wave Life Sciences Ltd 주식(WVE)의 최신 뉴스
Trading (WVE) With Integrated Risk Controls - Stock Traders Daily
Insider Sale: President and CEO Paul Bolno Sells 51,234 Shares o - GuruFocus.com
Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Sells $733,670.88 in Stock - MarketBeat
Wave Life Sciences CEO Paul Bolno sells shares for $733,670 By Investing.com - Investing.com UK
Wave Life Sciences CEO Paul Bolno sells shares for $733,670 - Investing.com
WVEWave Life Sciences Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
What is HC Wainwright's Forecast for WVE FY2028 Earnings? - MarketBeat
Wave Life Sciences to Present at Jefferies London Healthcare Conference - GlobeNewswire
What is B. Riley's Estimate for WVE Q1 Earnings? - MarketBeat
US$22.20That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results - Simply Wall St
Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20 - Yahoo Finance
Equities Analysts Offer Predictions for WVE FY2024 Earnings - MarketBeat
Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Wave Life Sciences Ltd. (NASDAQ:WVE) Short Interest Update - MarketBeat
WaVe Life Sciences's SWOT analysis: RNA editing stock faces pivotal year - Investing.com
Wave Life Sciences executive sells shares worth $576,000 By Investing.com - Investing.com Nigeria
Wave Life Sciences executive sells shares worth $576,000 - Investing.com India
Earnings call: Wave Life Sciences outlines transformative 2025 outlook By Investing.com - Investing.com Australia
Alpha-1 Antitrypsin Deficiency Market Expected to Experience Major Growth by 2034, According to DelveInsight | Kamada Pharma, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex - Barchart
Wave Life Sciences (NASDAQ:WVE) Given "Buy" Rating at HC Wainwright - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Wave Life Sciences outlines transformative 2025 outlook - Investing.com
WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Wave Life Sciences’ Q3 2024 Advances in RNA Therapies - TipRanks
Wave Life Sciences: Q3 Earnings Snapshot - CT Insider
Wave Life Sciences Ltd earnings missed by $0.19, revenue fell short of estimates - Investing.com Nigeria
Wave Life Sciences price target raised to $36 from $17 at Truist - TipRanks
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Wave Life Sciences files automatic mixed securities shelf - TipRanks
Q3 2024 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus.com
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Wave Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Wave Life Sciences Achieves First-Ever Human RNA Editing, Reports $310.9M Cash Position | WVE Stock News - StockTitan
WAVE Life Sciences Ltd (WVE) Q3 2024: Everything You Need to Kno - GuruFocus.com
Privium Fund Management B.V. Purchases Shares of 48,834 Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences (NASDAQ:WVE) Reaches New 12-Month HighStill a Buy? - MarketBeat
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking - Simply Wall St
WVE stock surges to 52-week high, touches $15.99 amid robust gains - Investing.com Australia
Wave Life Sciences treatment of Huntington’s disease gets FDA orphan designation - TipRanks
(WVE) On The My Stocks Page - Stock Traders Daily
Wave Life Sciences (WVE) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024 - StockTitan
B. Riley Issues Positive Forecast for Wave Life Sciences (NASDAQ:WVE) Stock Price - MarketBeat
Institutional investors in Wave Life Sciences Ltd. (NASDAQ:WVE) see US$94m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Emerald Advisers LLC Boosts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences' (WVE) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Those who invested in Wave Life Sciences (NASDAQ:WVE) three years ago are up 195% - Simply Wall St
Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs - The Manila Times
Wave Life Sciences Highlights Growing Pipeline at Research - GlobeNewswire
Wave Life Sciences Expands RNA Therapeutic Pipeline - TipRanks
Wave Life Sciences Ltd (WVE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):